Solid Tumor Therapeutics

University Of California, San Diego, La Jolla CA

Investigators

Linked publications & trials

Abstract

The mission of the Solid Tumor Therapeutics Program (STT) is to develop novel therapeutics and the diagnostic tools needed to individualize their use. The strategy for executing this mission involves a spectrum of basic, translational and clinical research efforts directed toward the identification of susceptible molecular targets, and validation of their importance to tumor behavior; the identification and preclinical testing of potential new drugs and diagnostics that can guide their use/ and, the clinical testing of new drugs, diagnostics and therapeutic strategies. The STT program is organized around 4 major research themes: inflammation and cancer, angiogenesis and metastasis, drug discovery, development targentin and teseing; and imaging development The STT Program has 82 members from 18 academic departments with $18.9 Million in peer review research grant funding (annual direct costs), including $7.6 Million from NCI. STT members published 1391 programmatically aligned articles (2007-2012); 10% were the result of intraprogrammatic collaborations, 11% were interprogrammatic.